All Fields
Computer Science
Medicine
FAQ
Contact
Sign in
LAF 237
Known as:
LAF-237
, LAF237
Â
Â
National Institutes of Health
Topic mentions per year
Topic mentions per year
2004-2016
0
1
2
3
2004
2016
Related topics
Related topics
1 relation
Broader (1)
vildagliptin
Related mentions per year
Related mentions per year
2004-2018
2000
2005
2010
2015
2020
LAF 237
vildagliptin
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
Dipeptidyl peptidase-IV inhibitors used in type-2 diabetes inhibit a phospholipase C: a case of promiscuous scaffolds in proteins
S. T. Chakraborty
,
Adela Rendón-RamÃrez
,
+11 authors
Adela Rendón-RamÃrez
F1000Research
2013
The long term side effects of any newly introduced drug is a subject of intense research, and often raging controversies. One…Â
(More)
Is this relevant?
Highly Cited
2012
Highly Cited
2012
Dipeptidyl peptidase IV inhibitor attenuates kidney injury in streptozotocin-induced diabetic rats.
Wei Jing Liu
,
Shu Hua Xie
,
+5 authors
Tae Sun Park
The Journal of pharmacology and experimental…
2012
Dipeptidyl peptidase (DPP) IV inhibitors are probably beneficial for preventing diabetic complication and modulating glucagon…Â
(More)
Is this relevant?
2012
2012
The Synergistic Effect of Valsartan and LAF237 [(S)-1-[(3-Hydroxy-1-Adamantyl)Ammo]acetyl-2-Cyanopyrrolidine] on Vascular Oxidative Stress and Inflammation in Type 2 Diabetic Mice
Min Shen
,
Dongdong Sun
,
+4 authors
Feng Cao
Experimental diabetes research
2012
AIM To investigate the combination effects and mechanisms of valsartan (angiotensin II type 1 receptor blocker) and LAF237 (DPP…Â
(More)
Is this relevant?
2012
2012
Ligand-based pharmacophore detection, screening of potential gliptins and docking studies to get effective antidiabetic agents.
Ritesh Agrawal
,
Pratima Jain
,
Subodh Narayan Dikshit
Combinatorial chemistry & high throughput…
2012
Three-dimensional pharmacophore hypothesis was established based on a set of known DPP-IV inhibitor using PharmaGist software…Â
(More)
Is this relevant?
2011
2011
The DPP-4 inhibitor vildagliptin increases pancreatic beta cell mass in neonatal rats.
Alokesh Duttaroy
,
Frank Voelker
,
+5 authors
Bryan F. Burkey
European journal of pharmacology
2011
The present study addressed the effect of the dipeptidyl peptidase-4 (DPP-4) inhibitor vildagliptin ((1-[[(3-hydroxy-1-adamantyl…Â
(More)
Is this relevant?
2011
2011
Fibroblast activation protein-α promotes tumor growth and invasion of breast cancer cells through non-enzymatic functions
Yan Huang
,
Avis E. Simms
,
+5 authors
Thomas Kelly
Clinical & Experimental Metastasis
2011
Fibroblast activation protein-α (FAP) is a cell surface, serine protease of the post-prolyl peptidase family that is expressed in…Â
(More)
Is this relevant?
2008
2008
Combination of the dipeptidyl peptidase IV inhibitor LAF237 [(S)-1-[(3-hydroxy-1-adamantyl)ammo]acetyl-2-cyanopyrrolidine] with the angiotensin II type 1 receptor antagonist valsartan [N-(1-oxopentyl…
Qianni Cheng
,
Pui ki Law
,
Marc de Gasparo
,
Po Sing Leung
The Journal of pharmacology and experimental…
2008
LAF237 [(S)-1-[(3-hydroxy-1-adamantyl)ammo]acetyl-2-cyanopyrrolidine] is an inhibitor of dipeptidyl peptidase IV that delays the…Â
(More)
Is this relevant?
2007
2007
Combination of dipeptidylpeptidase IV inhibitor and low dose thiazolidinedione: preclinical efficacy and safety in db/db mice.
Subhasis Mitra Roy
,
V Gopiesh Khanna
,
+8 authors
Vinay Sheel Bansal
Life sciences
2007
Thiazolidinediones (TZDs) are currently the most efficacious class of oral antidiabetics. However, they carry the burden of…Â
(More)
Is this relevant?
Highly Cited
2005
Highly Cited
2005
Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response.
Smiljana Ristić
,
Stuart Byiers
,
Jennifer A Foley
,
Douglas P Holmes
Diabetes, obesity & metabolism
2005
OBJECTIVE A novel treatment option for diabetic patients is the enhancement of incretin hormone activity by inhibition of the…Â
(More)
Is this relevant?
Highly Cited
2004
Highly Cited
2004
Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes.
Bo Ahrén
,
Ramón Morell Gomis
,
Eberhard Standl
,
David P Mills
,
Anja Schweizer
Diabetes care
2004
OBJECTIVE To assess the 12- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 versus placebo in patients with…Â
(More)
Is this relevant?